FDA Approves EPRONTIA — Azurity Pharmaceuticals, Inc.

# FDA Approves Azurity Pharmaceuticals' EPRONTIA (Topiramate) for Oral Administration Azurity Pharmaceuticals, Inc. has received FDA approval for EPRONTIA (topiramate) oral formulation, expanding the competitive landscape in the established topiramate market and positioning Azurity to capture market share in the anticonvulsant and migraine prevention segments. The approval of NDA214679 strengthens Azurity's portfolio in high-volume generic therapeutics and offers healthcare providers an additional branded option in a market already populated with multiple topiramate alternatives.